Mirati Therapeutics (MRTX) PT Lowered to $60 at Morgan Stanley
Tweet
Share
E-mailGet Alerts MRTX Hot Sheet
Price: $58.70 --0%
Rating Summary:
8 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
8 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
Morgan Stanley analyst Michael Ulz lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $60.00 (from $70.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Citi Downgrades DHL Group (DHL:GR) to Neutral
- Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
- Nomura/Instinet Downgrades Lloyds Metals & Energy Ltd (LLOYDSME:IN) to Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
